登录 | 注册    关注公众号  
微信公众号
搜索
 >  Protein>B7-2 >CD6-H5257

Human B7-2 / CD86 Protein, Fc Tag, premium grade

分子别名(Synonym)

CD86,B7-2,B70,CD28LG2,LAB72,MGC34413

表达区间及表达系统(Source)

Human B7-2, Fc Tag, premium grade (CD6-H5257) is expressed from human 293 cells (HEK293). It contains AA Leu 26 - Pro 247 (Accession # AAH40261 ).

Predicted N-terminus: Leu 26

It is produced under our rigorous quality control system that incorporates a comprehensive set of tests including sterility and endotoxin tests. Product performance is carefully validated and tested for compatibility for cell culture use or any other applications in the early preclinical stage. When ready to transition into later clinical phases, we also offer a custom GMP protein service that tailors to your needs. We will work with you to customize and develop a GMP-grade product in accordance with your requests that also meets the requirements for raw and ancillary materials use in cell manufacturing of cell-based therapies.

Request for sequence

蛋白结构(Molecular Characterization)

B7-2 Structure

This protein carries a human IgG1 Fc tag at the C-terminus.

The protein has a calculated MW of 51.5 kDa. The protein migrates as 66-100 kDa under reducing (R) condition, and 120-140 kDa under non-reducing (NR) condition (SDS-PAGE) due to glycosylation.

内毒素(Endotoxin)

Less than 0.01 EU per μg by the LAL method.

无菌(Sterility)

The sterility testing was performed by membrane filtration method.

支原体(Mycoplasma)

Negative.

纯度(Purity)

>95% as determined by SDS-PAGE.

>90% as determined by SEC-MALS.

制剂(Formulation)

Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 100 mM Glycine, 25 mM Arginine, 10 mM NaCl, pH7.5 with trehalose as protectant.

Contact us for customized product form or formulation.

重构方法(Reconstitution)

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

存储(Storage)

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

  1. -20°C to -70°C for 12 months in lyophilized state;
  2. -70°C for 3 months under sterile conditions after reconstitution.
 

电泳(SDS-PAGE)

B7-2 SDS-PAGE

Human B7-2, Fc Tag, premium grade on SDS-PAGE under reducing (R) and non-reducing (NR) conditions. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

SEC-MALS

B7-2 SEC-MALS

The purity of Human B7-2, Fc Tag, premium grade (Cat. No. CD6-H5257) is more than 90% and the molecular weight of this protein is around 120-150 kDa verified by SEC-MALS.

Report

 

活性(Bioactivity)-FACS

B7-2 FACS

Flow Cytometry assay shows that recombinant Human B7-2, Fc Tag, premium grade (Cat.No. CD6-H5257) can bind to CD28 expressed on Jurkat E6.1. The concentration of B7-2 used is 2 μg/ml (Routinely tested).

Protocol

B7-2 FACS

FACS analysis shows that the binding of Human B7-2, Fc Tag, premium grade (Cat. No. CD6-H5257) to CD28 expressed on Jurkat E6.1 was inhibited by increasing concentration of neutralizing anti-CD28 antibody. The concentration of B7-2 used is 2 μg/ml. The IC50 is 0.022 μg/ml (Routinely tested).

Protocol

B7-2 FACS

FACS assay shows that Human B7-2, Fc Tag, premium grade (Cat. No. CD6-H5257) can bind to 293T cells overexpressing human CTLA4 protein. The concentration of Human B7-2 is 3 μg/ml (Routinely tested).

Protocol

 

活性(Bioactivity)-ELISA

B7-2 ELISA

Immobilized Human B7-2, Fc Tag, premium grade (Cat. No. CD6-H5257) at 5 μg/mL (100 μL/well) can bind Biotinylated Human CTLA-4, Fc,Avitag (Cat. No. CT4-H82F3) with a linear range of 0.6-10 ng/mL (QC tested).

Protocol

B7-2 ELISA

Immobilized Biotinylated Mouse CD28, His,Avitag (Cat. No. CD8-M82E3) at 1 μg/mL (100 μL/well) on Streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate, can bind Human B7-2, Fc Tag, premium grade (Cat. No. CD6-H5257) with a linear range of 5-78 ng/mL (Routinely tested).

Protocol

B7-2 ELISA

Immobilized Biotinylated Human / Cynomolgus / Rhesus macaque CD28, His,Avitag (Cat. No. CD8-H82E5) at 1 μg/mL (100 μL/well) on Streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate, can bind Human B7-2, Fc Tag, premium grade (Cat. No. CD6-H5257) with a linear range of 2-78 ng/mL (Routinely tested).

Protocol

 

活性(Bioactivity)-BLI

B7-2 BLI

Loaded Human B7-2, Fc Tag, premium grade (Cat. No. CD6-H5257) on Protein A Biosensor, can bind Human / Cynomolgus / Rhesus macaque CD28, His Tag (Cat. No. CD8-H52Hc) with an affinity constant of 4.5 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Protocol

B7-2 BLI

Loaded Human B7-2, Fc Tag, premium grade (Cat. No. CD6-H5257) on Protein A Biosensor, can bind Human CTLA-4, His Tag (Cat. No. CT4-H52H9) with an affinity constant of 1.03 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Protocol

 

背景(Background)

Cluster of Differentiation 86 (CD86) is also known as B-lymphocyte activation antigen B7-2, is a type I membrane protein that is a member of the immunoglobulin superfamily, and is constitutively expressed on interdigitating dendritic cells, Langerhans cells, peripheral blood dendritic cells, memory B cells, and germinal center B cells. Additionally, B72 is expressed at low levels on monocytes and can be upregulated through interferon γ. CD86 is the ligand for two different proteins on the T cell surface: CD28 (for autoregulation and intercellular association) and CTLA-4 (for attenuation of regulation and cellular disassociation). CD86 works in tandem with CD80 to prime T cells. Recent study has revealed that B7-2 promotes the generation of a mature APC repertoire and promotes APC function and survival. Furthermore, the B7 proteins are also involved in innate immune responses by activating NF-κB-signaling pathway in macrophages. CD86 thus is regarded as a promising candidate for immune therapy. CD86+ macrophages in Hodgkin lymphoma patients are an independent marker for potential nonresponse to firstline-therapy.

文献引用(Citations)

 

前沿进展

 
 
货号/价格
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
B7-2靶点信息
英文全称:Cluster of differentiation 86
中文全称:分化群86
种类:Homo sapiens
上市药物数量:2详情
临床药物数量:5详情
最高研发阶段:批准上市
查看更多信息
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定